IDH1 and central nervous system cancer: In this study, the IDH1 mutation in WHO grade III and grade IV glioma-enhanced images was studied, which not only confirms the reliability of radiomics in the study of IDH1 mutations in gliomas of different grades but also broadens its application scope.